Published in Oncoimmunology on January 01, 2013
Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol (2008) 3.41
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood (2008) 2.04
PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes. PLoS One (2012) 1.16
The dilemma of anticancer therapy: tumor-specific versus immune effects. Blood (2008) 1.08
Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clin Cancer Res (2012) 1.03
Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts. PLoS One (2012) 0.94
Signal interception-based therapies--a double-edged sword in Bcr/abl-induced malignancies? Leuk Lymphoma (2008) 0.83
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology (2011) 2.33
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
The ubiquitin-specific protease Usp4 regulates the cell surface level of the A2A receptor. Mol Pharmacol (2005) 2.21
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood (2008) 2.04
STAT1 acts as a tumor promoter for leukemia development. Cancer Cell (2006) 2.00
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol (2012) 1.77
Laryngeal recurrent nerve injury in surgery for benign thyroid diseases: effect of nerve dissection and impact of individual surgeon in more than 27,000 nerves at risk. Ann Surg (2002) 1.69
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol (2013) 1.63
Neuromonitoring in thyroid surgery: prospective evaluation of intraoperative electrophysiological responses for the prediction of recurrent laryngeal nerve injury. Ann Surg (2004) 1.61
[The Club of Female Professors of the Medical University Vienna]. Wien Med Wochenschr (2009) 1.60
The N terminus of monoamine transporters is a lever required for the action of amphetamines. J Biol Chem (2010) 1.58
A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood (2010) 1.50
Concentrative export from the endoplasmic reticulum of the gamma-aminobutyric acid transporter 1 requires binding to SEC24D. J Biol Chem (2007) 1.49
Selective serotonin reuptake inhibitors--a new modality for the treatment of lymphoma/leukaemia? Biochem Pharmacol (2007) 1.44
Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action. Mol Pharmacol (2005) 1.42
Anomalous dopamine release associated with a human dopamine transporter coding variant. J Neurosci (2008) 1.41
Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal (2002) 1.39
The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J (2002) 1.38
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
The reverse operation of Na(+)/Cl(-)-coupled neurotransmitter transporters--why amphetamines take two to tango. J Neurochem (2009) 1.36
Identification of an additional interaction domain in transmembrane domains 11 and 12 that supports oligomer formation in the human serotonin transporter. J Biol Chem (2003) 1.25
Unifying concept of serotonin transporter-associated currents. J Biol Chem (2011) 1.24
Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res (2004) 1.22
The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter. Mol Pharmacol (2010) 1.21
Ligand-based peptide design and combinatorial peptide libraries to target G protein-coupled receptors. Curr Pharm Des (2010) 1.20
Two discontinuous segments in the carboxyl terminus are required for membrane targeting of the rat gamma-aminobutyric acid transporter-1 (GAT1). J Biol Chem (2004) 1.20
The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. J Biol Chem (2012) 1.19
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood (2007) 1.18
PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes. PLoS One (2012) 1.16
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol (2008) 1.15
Ca(2+)/calmodulin-dependent protein kinase IIα (αCaMKII) controls the activity of the dopamine transporter: implications for Angelman syndrome. J Biol Chem (2012) 1.14
Mutational analysis of the high-affinity zinc binding site validates a refined human dopamine transporter homology model. PLoS Comput Biol (2013) 1.14
The conserved glutamate (Glu136) in transmembrane domain 2 of the serotonin transporter is required for the conformational switch in the transport cycle. J Biol Chem (2006) 1.13
Sec24- and ARFGAP1-dependent trafficking of GABA transporter-1 is a prerequisite for correct axonal targeting. J Neurosci (2008) 1.12
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget (2012) 1.12
The role of zinc ions in reverse transport mediated by monoamine transporters. J Biol Chem (2002) 1.11
The serotonin transporter is an exclusive client of the coat protein complex II (COPII) component SEC24C. J Biol Chem (2011) 1.11
A quantitative model of amphetamine action on the 5-HT transporter. Br J Pharmacol (2014) 1.11
JunB inhibits proliferation and transformation in B-lymphoid cells. Blood (2003) 1.10
Mutations within an intramembrane leucine heptad repeat disrupt oligomer formation of the rat GABA transporter 1. J Biol Chem (2002) 1.09
Mutations in the carboxyl-terminal SEC24 binding motif of the serotonin transporter impair folding of the transporter. J Biol Chem (2010) 1.08
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Oxytocic plant cyclotides as templates for peptide G protein-coupled receptor ligand design. Proc Natl Acad Sci U S A (2013) 1.07
The different functions of Stat5 and chromatin alteration through Stat5 proteins. Front Biosci (2008) 1.05
Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL. J Immunol (2009) 1.05
Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood (2010) 1.04
The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. Biol Chem (2011) 1.03
Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front Biosci (Landmark Ed) (2011) 1.02
JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood (2013) 1.02
CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep (2013) 1.02
The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation. J Leukoc Biol (2010) 1.01
Signal-dependent export of GABA transporter 1 from the ER-Golgi intermediate compartment is specified by a C-terminal motif. J Cell Sci (2008) 1.00
The tumor suppressor function of STAT1 in breast cancer. JAKSTAT (2013) 1.00
Conditional Stat1 ablation reveals the importance of interferon signaling for immunity to Listeria monocytogenes infection. PLoS Pathog (2012) 0.99
Truncation of the A1 adenosine receptor reveals distinct roles of the membrane-proximal carboxyl terminus in receptor folding and G protein coupling. J Biol Chem (2003) 0.99
Oligomer formation by Na+-Cl--coupled neurotransmitter transporters. Eur J Pharmacol (2003) 0.99
MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol (2013) 0.98
Macrophage and T cell produced IL-10 promotes viral chronicity. PLoS Pathog (2013) 0.98
Electron microscopic visualization of fluorescent signals in cellular compartments and organelles by means of DAB-photoconversion. Histochem Cell Biol (2008) 0.98
VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution. Cardiovasc Res (2012) 0.98
The carboxyl terminus of the Galpha-subunit is the latch for triggered activation of heterotrimeric G proteins. Mol Pharmacol (2005) 0.98
Removal of the carboxy terminus of the A2A-adenosine receptor blunts constitutive activity: differential effect on cAMP accumulation and MAP kinase stimulation. Naunyn Schmiedebergs Arch Pharmacol (2002) 0.96
The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. Front Biosci (Landmark Ed) (2009) 0.96
Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol (2005) 0.96
Recruitment of a cytoplasmic chaperone relay by the A2A adenosine receptor. J Biol Chem (2013) 0.96
Molecular dissection of dual pseudosymmetric solute translocation pathways in human P-glycoprotein. Mol Pharmacol (2010) 0.95
Switching the clientele: a lysine residing in the C terminus of the serotonin transporter specifies its preference for the coat protein complex II component SEC24C. J Biol Chem (2013) 0.95
Peptide-based interactions with calnexin target misassembled membrane proteins into endoplasmic reticulum-derived multilamellar bodies. J Mol Biol (2008) 0.95
TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest (2004) 0.95
The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas. Blood (2011) 0.94
Probing binding pocket of serotonin transporter by single molecular force spectroscopy on living cells. J Biol Chem (2011) 0.94
Intra- and postoperative parathyroid hormone-kinetics do not advocate for autotransplantation of discolored parathyroid glands during thyroidectomy. Thyroid (2010) 0.94
From cradle to twilight: the carboxyl terminus directs the fate of the A(2A)-adenosine receptor. Biochim Biophys Acta (2010) 0.94
Inhibition of adenylyl cyclase by neuronal P2Y receptors. Br J Pharmacol (2002) 0.93
Evolution of nerve injury with unexpected EMG signal recovery in thyroid surgery using continuous intraoperative neuromonitoring. World J Surg (2013) 0.92
Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget (2011) 0.92
MAP kinase stimulation by cAMP does not require RAP1 but SRC family kinases. J Biol Chem (2002) 0.92
Restricted collision coupling of the A2A receptor revisited: evidence for physical separation of two signaling cascades. J Biol Chem (2008) 0.92
Pharmacochaperoning of the A1 adenosine receptor is contingent on the endoplasmic reticulum. Mol Pharmacol (2010) 0.91
The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J Invest Dermatol (2005) 0.91
c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6. Blood (2011) 0.91